TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03925597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.
Study: NCT01568996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract - sulforaphane (BSE-SFN)
Description: 100 µmol capsules, taken orally, once a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract - sulforaphane (BSE-SFN)
Description: 200 µmol capsules, taken orally, once a day for 28 days
Study: NCT02404064

Intervention type: DRUG
Group type: OTHER
Intervention: cefamezin 1g IV
Description: perioperative antibiotics (Cefamizin 1g IV; )

Intervention type: DRUG
Group type: OTHER
Intervention: metronidazole 500 mg IV
Description: perioperative antibiotics (metronidazole 500 mg IV )
Study: NCT02680717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol
Description: ointment, twice daily (alternating weeks)
Study: NCT02404064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No perioperative antibiotics
Study: NCT01842971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two stage hepatectomy
Study: NCT03037190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: withdrawal of gluten from the diet
Description: Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
Study: NCT03674190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Lumbar Interbody Fusion
Description: Anterior Lumbar Fusion(ALIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Disc Replacement
Description: Total Disc Replacement
Study: NCT01884064

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS
Study: NCT02595827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conditional Advice
Description: Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
Study: NCT04572672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting
Description: Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study.
Study: NCT03150563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive static stretch
Description: Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive static stretch
Description: Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive static stretch
Description: Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
Study: NCT02678052

Intervention type: DRUG
Intervention: Vedolizumab
Description: Vedolizumab exposure

Intervention type: BIOLOGICAL
Intervention: Other Biological Agent
Description: Other Biological Agent exposure
Study: NCT02521844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1922159
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1922159
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV administration
Study: NCT04102449

Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Single arm receiving Apremilast and ultrasound examinations
Study: NCT03055767

Intervention type: DRUG
Group type: OTHER
Intervention: OnabotulinumtoxinA
Description: The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.

Intervention type: DRUG
Group type: OTHER
Intervention: OnabotulinumtoxinA
Description: The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
Study: NCT00682916

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Y288
Description: Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
Study: NCT01784016

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-PHNO
Description: \[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-PHNO
Description: \[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
Study: NCT02666417

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge (MNP+iron)
Description: Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge (MNP+iron+GOS)
Description: Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
Study: NCT00277043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, docetaxel, taxane
Description: 1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxane
Description: The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
Study: NCT02719704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEXA-SE
Description: MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Espelho, espelho meu
Description: Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters.
Study: NCT03055767

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (Saline)
Description: The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (Saline)
Description: The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
Study: NCT02759731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
Study: NCT03883438

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified coronally advanced flap and acellular dermal matrix graft
Description: Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced flap and acellular dermal matrix graft
Description: Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
Study: NCT00906620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPR: question, persuade and refer (SEYLE)
Description: The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies.
Study: NCT01680094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
Study: NCT00760227

Intervention type: OTHER
Group type: OTHER
Intervention: Massage Therapy
Description: Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.

Intervention type: OTHER
Group type: OTHER
Intervention: Massage Therapy
Description: Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.

Intervention type: OTHER
Group type: OTHER
Intervention: Humor Therapy
Description: For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.

Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation Therapy
Description: In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
Study: NCT03622593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
Study: NCT03257930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol injection
Description: inject ethanol in cystic thyroid nodule and follow up until complete recovery
Study: NCT01013909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifonazole spray once daily
Description: Application of one dose daily by means of an metered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifonazole spray twice daily
Description: Application of two dose daily by means of an metered dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of one dose daily by means of an metered dose
Study: NCT02438696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, iFF, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, iFF, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF1, Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF2, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF2, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, iFF, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF1, Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, iFF, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, iFF, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF1, Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF2, Test
Study: NCT02680717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene
Description: ointment, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: ointment, 0.1%, twice daily
Study: NCT02254941

Intervention type: DRUG
Intervention: Chemotherapy
Description: Metastatic colon cancer, first line treatment with conventional chemotherapy

Intervention type: BIOLOGICAL
Intervention: Chemotherapy plus monoclonal antibody
Description: Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
Study: NCT03760055

Intervention type: DEVICE
Intervention: nGoggle
Description: The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.

Intervention type: DEVICE
Intervention: nGoggle
Description: The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.

Intervention type: DEVICE
Intervention: nGoggle
Description: The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
Study: NCT02438696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF1, Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF1, Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF2, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF2, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, iFF, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF2, Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF1, Reference
Study: NCT03760055

Intervention type: DEVICE
Intervention: nGoggle
Description: The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
Study: NCT00302185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led supportive care
Description: 20-30 minutes of supportive attention from an experienced palliative nurse.
Study: NCT01013909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of one dose daily by means of an metered dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil Once
Description: One application of Lamisil Once
Study: NCT03660813

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follicle measurment
Description: Follicle will be measured before aspiration

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follicle measurment
Description: Follicle will be measured before aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle ( Hcg 250 mcg)
Description: Drug used for triggering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle ( Hcg 250 mcg)
Description: Drug used for triggering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl ( GnRH Agonist 0.1 mg*2 )
Description: Drug used for triggering
Study: NCT02547831

Intervention type: OTHER
Intervention: Observational approach
Description: Patients will be placed under wait and see approach without any specific treatment